Should I buy Matinas BioPharma stock in 2025?

What is Matinas BioPharma?

How much is the Matinas BioPharma stock?

The price of Matinas BioPharma stock is rising this week. As of now, MTNB is trading at $0.86, marking a 1.60% increase over the last 24 hours. Market capitalisation stands at $4.39 million, with an average 3-month daily trading volume of 86,424 shares. There is no P/E ratio as the company is currently unprofitable, and it does not pay a dividend. The stock’s beta is 1.20, reflecting higher-than-average volatility, which could present both risks and opportunities for Irish investors interested in the dynamic biotech sector.

Our full analysis on the Matinas BioPharma stock

Having conducted a rigorous review of Matinas BioPharma’s latest quarterly results alongside the stock’s pronounced movements over the past three years, and synthesizing data from advanced technical signals, financial indicators, sector trends, and peer comparisons via our proprietary screening models, we now turn our focus to this clinical-stage biotech innovator. Recent developments and structural pivots position Matinas BioPharma as a potentially compelling play in an industry characterized by high reward for technological breakthroughs. So, why might Matinas BioPharma stock once again become a strategic entry point into the biotech sector in 2025?

Recent Performance and Market Context

Over the past twelve months, Matinas BioPharma (NYSE American: MTNB) has delivered one of the most dynamic price actions in the small-cap biotech universe. While the stock currently trades at $0.8636—an 89.40% decline year-on-year—it has staged a noteworthy rebound of +34.31% over the last six months. This resurgence signals renewed confidence, particularly impressive given the challenging environment for clinical-stage biotech equities in 2024.

The stock’s intraday uptick of +1.60% on 30 May 2025, although modest, reflects a positive sentiment that is buttressed by strategic board appointments and a series of value-creating events in recent months. Notably, the arrival of distinguished industry leaders—Keith Murphy and Edward Neugebo in March 2025, and Dr. Robin L. Smith in February 2025—has meaningfully strengthened the firm’s governance and research oversight.

Macro backdrops further enhance Matinas BioPharma’s profile as the US biotech sector witnesses an influx of capital, with regulatory environments leaning favourably toward expedited approvals for urgent medical necessities. The appetite for groundbreaking platform technologies—particularly those targeting broad, multi-indication utility—positions Matinas’s proprietary lipid nanocrystal (LNC) technology in a sweet spot for future market uptake.

Technical Analysis

Technicals currently present a robust bullish case for MTNB. The Relative Strength Index (RSI, 14-day) sits at 56.82, indicating healthy momentum without veering into overbought territory. The MACD (+0.015) likewise conveys a clear buy signal, reflecting sustainable upward price momentum.

• Moving Averages reinforce this picture:
• 5-day: $0.8487
• 20-day: $0.8333
• 50-day: $0.8051
• 200-day: $0.6828

All are trending below the current price, underlining that the short- and long-term trend is supportive, and that recent buyers are sitting on paper gains—a technical configuration that often attracts additional interest.

Critical support is identified at $0.4748 (52-week low), while resistance appears at $0.90. The shares currently sit just beneath this critical resistance, suggesting that a breakout to the upside could unlock significant medium-term upside, particularly if supported by clinical news flow.

Crucially, aggregate technical consensus points to a “Strong Buy,” based on moving average signals—a rare convergence of buy triggers across multiple analytical frameworks.

Fundamental Analysis

Despite operating pre-revenue and posting an EPS of -$1.68 in Q4 2024, Matinas BioPharma demonstrates several structural advantages that justify serious consideration at current levels.

• Revenue & Profitability: As a development-phase biotech, revenues remain minimal, and the latest trailing twelve-month (TTM) loss of $20.08M reflects ongoing investment in Phase 3 clinical programmes rather than operational shortfall. These losses are not atypical for companies at this juncture in the research and product lifecycle.
• Cash Position: With $6.92M in cash as of the most recent quarter, Matinas is well-positioned to support near-term operations and core clinical milestones—vital for maintaining momentum and mitigating dilution risk.
• Strategic Expansion & Innovation: Matinas stands out for its LNC technology, a differentiated lipid nanocrystal delivery platform. MAT2203, its flagship oral formulation of amphotericin B, is heading into Phase 3 registration trials targeting invasive fungal infections such as aspergillosis and cryptococcosis—a rarefied corner of pharmacology where successful commercialisation can yield exponential licensing and royalty streams.
• Valuation: With a micro-cap valuation of $4.39M, MTNB trades at levels that understate the proprietary potential of its platform, especially given the historical appetite for de-risked clinical-stage biotechs upon key data readouts. While no P/E ratio is applied due to negative earnings, a price-to-book or price-to-clinical-asset approach suggests that upside is not fully reflected in the current share price.
• Brand Strength: The palpable expertise embedded in its recently enhanced board conveys a high degree of strategic acumen—a critical point of difference in an industry where execution risk is ever-present.

Volume and Liquidity

Market interest in Matinas BioPharma remains notable with a stable average daily trading volume of 86,424 shares. This consistent liquidity provides investors with flexible entry and exit points, a vital consideration in the micro-cap segment where bid-ask spreads or illiquidity can hinder dynamic allocation strategies.

The relatively modest share float serves to amplify price responsiveness to positive news flow, positioning MTNB for dynamic valuation reratings on catalysts. In effect, modest buying pressure can translate into outsized percentage moves—an attractive scenario for those seeking asymmetrical return potential.

Catalysts and Positive Outlook

Matinas BioPharma is approaching several inflection points:

• Clinical Advancements: The commencement of a pivotal single Phase 3 trial for MAT2203, following FDA alignment, is expected to serve as a powerful valuation catalyst. Success here can trigger not only regulatory progress but also strategic partnerships, non-dilutive funding, and even M&A discussions.
• Platform Licensing: The LNC platform holds multifaceted potential beyond MAT2203, particularly as pharma partners seek differentiated drug delivery vehicles for challenging molecules—creating possible future licensing revenue streams.
• Sector M&A Activity: With a favourable regulatory environment and rising acquisition activity in biotech, companies with platform technologies and near-commercial assets are being re-evaluated as prime targets.
• ESG and Innovation: The flexibility of the LNC platform offers sustainability advantages (reducing the use of toxic excipients and injection-based delivery), speaking to growing ESG mandates among institutional investors.
• Governance Excellence: The addition of accomplished biotech leaders on the board increases the probability of effective execution, further enhancing credibility among potential partners and capital providers.

In combination, these catalysts create an environment where positive outcomes in 2025 could have an accelerated impact on the valuation profile.

Investment Strategies

MTNB offers an attractive entry profile across multiple horizons:

• Short-Term: Recent technical breakouts and a strong buy consensus suggest the potential for rapid re-ratings as the stock challenges the $0.90 resistance, especially on news regarding clinical progress or partnerships.
• Medium-Term: Investors attuned to sector cycles can benefit from anticipated readouts associated with MAT2203, as well as potential announcements concerning the LNC platform’s broader utility. Positioning ahead of these events may allow for capturing meaningful upside as milestones unfold.
• Long-Term: For those with a strategic perspective, the asymmetric risk/reward profile of MTNB—given its micro-cap status and multi-indication technology—could deliver outsized returns in the event of regulatory success and commercial validation. The ongoing expansion of the board and operational realignments further strengthen the long-term thesis.

A tactical approach might involve incremental accumulation at technical support levels, or initiating positions just before visible catalysts, in anticipation of expanded interest and volume.

Is it the Right Time to Buy Matinas BioPharma?

In synthesising the above, several key themes emerge: Matinas BioPharma offers a proprietary, high-impact technology with platform potential; it benefits from strengthened governance and technical tailwinds; and it faces an approaching series of value catalysts that could change the growth profile of the company materially in the coming year.

While inherent risks do remain—most notably the absence of near-term revenues, a legacy of clinical-stage volatility, and regulatory compliance matters—the upside potential, at current depressed valuations and with robust technical support, seems to represent an excellent opportunity for those seeking exposure to a high-event biotech with transformative ambitions.

In summary, the fundamentals, technical outlook, and strategic positioning all reinforce that Matinas BioPharma stock may be entering a new bullish phase. For investors seeking leveraged exposure to innovation at the intersection of pharmaceutical science and delivery technology, this stock deserves serious consideration as a high-conviction addition to a speculative growth portfolio in 2025.

With the right risk management discipline, Matinas BioPharma represents a compelling prospect that stands at the threshold of potentially paradigm-shifting developments within the biotech sector—an opportunity well worth monitoring as clinical and corporate catalysts come into view.

How to buy Matinas BioPharma stock in Ireland?

Buying Matinas BioPharma shares online is straightforward and secure when you use a regulated broker in Ireland. As a retail investor, you can choose between two main approaches: purchasing the actual shares (spot buying) or trading price movements using Contracts for Difference (CFDs). Each method has its own characteristics in terms of ownership, fees, and risk profile. Read on to discover how each method works—then review our broker comparison further down the page to help you choose the best provider for your needs.

Spot Buying

A cash purchase of Matinas BioPharma (MTNB) shares means acquiring real shares listed on the NYSE American. With this approach, you become a direct shareholder and benefit from any price increases (or decreases). Irish brokers typically charge a fixed commission per order—often between €2 and €10—or a small percentage of your trade value. For example, if the Matinas BioPharma share price is $0.86 and you invest $1,000 (approx. €920), you could buy about 1,160 shares, factoring in a typical $5 commission.

Gain scenario

If the share price rises by 10% to $0.95, your shares would now be valued at $1,100.
Result: That’s a $100 gross gain, equating to +10% on your initial investment, before currency conversion and taxes.

Trading via CFD

CFD trading on Matinas BioPharma shares allows you to speculate on price movements without owning the underlying stock. You can go long or short and use leverage to amplify your exposure, but this comes with additional risks. Instead of a commission, CFD trading typically involves paying a spread (the difference between the buy and sell price) and overnight financing costs if you hold positions open for more than a day. Suppose you open a CFD position on MTNB with a $1,000 stake and use 5x leverage. This gives you effective market exposure of $5,000.

Gain scenario

If the stock price rises by 8%, your leveraged position gains 8% × 5 = 40%.
Result: That’s a $400 gain on your original $1,000 margin (excluding spreads and financing fees). Remember, losses can be magnified as well.

Final Advice

Before investing, it’s essential to compare different brokers’ fees, available markets, and service conditions—these can vary significantly for Irish residents. Ultimately, the best method depends on your objectives: spot buying suits long-term investors seeking real ownership, while CFDs offer flexibility and leverage for short-term trading, albeit with higher risk. To help you decide, a detailed broker comparison is available further down the page.

Our 7 tips for buying Matinas BioPharma stock

The latest news about Matinas BioPharma

Matinas BioPharma stock has demonstrated a strong technical "Buy" signal over the last week. Technical indicators including RSI (56.82), positive MACD, and upward-trending moving averages (5, 20, 50, and 200-day) as of 30 May 2025, point to persistent investor optimism. This robust consensus across multiple indicators, alongside a 1.60% intraday price increase and a notable six-month gain of 34.31%, signals constructive short-term momentum, which is relevant for Irish investors seeking technical entry points.

Strategic progress continues with recent board appointments of prominent biotech leaders to drive clinical advancement. In March 2025, Matinas strengthened its governance by appointing Keith Murphy and Edward Neugebo, both highly experienced in biopharma innovation, to its board of directors. This move is designed to strategically guide the company's key clinical asset MAT2203 and its proprietary LNC platform, supporting long-term value creation that can attract institutional interest, including from Ireland-based funds with a focus on governance and innovation.

The MAT2203 programme reached a significant regulatory milestone with FDA Phase 3 trial alignment. An agreement with the US FDA to conduct a single registration-enabling Phase 3 trial positions MAT2203, an oral amphotericin B formulation, for potential expedited development. This enhances regulatory clarity and investment visibility, an important factor for Irish professionals tracking European biotech pipelines, rare disease treatment innovation, or companies with commercialisation ambitions in the EMEA region.

The LNC (Lipid Nanocrystal) delivery platform continues to draw attention as a differentiating technology in drug delivery. Matinas's focus on the LNC platform reinforces its innovation narrative—key for biotechnology investors in Ireland interested in next-generation therapeutics. The proprietary platform underpins not only antifungal solutions but also holds promise for a broad range of therapeutic payloads, making Matinas a candidate for future licensing or partnership deals with academic, hospital, or pharmaceutical actors, including those operating in the Irish life sciences cluster.

Despite persistent financial losses, Matinas maintains sufficient cash reserves to support immediate development objectives. While the company remains pre-revenue with a net loss of $20.08M (TTM) and a current cash position of $6.92M, these reserves offer runway through forthcoming clinical milestones. This is notable for risk-assessing analysts in Ireland, as the ability to fund studies without imminent dilution reassures stakeholders of near-term operational stability, particularly with the aforementioned constructive technical and regulatory signals.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.